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Abstract
Background
Women taking lithium must decide whether to continue the medication if they conceive or
plan to conceive. Little is known about the extent of prescribing of lithium during pregnancy.
Aims
To determine: 1) the prevalence of lithium prescribing during pregnancy and 2) to assess
whether pregnancy is associated with discontinuation of lithium.
Method
First, we identified women receiving any lithium prescriptions before and during pregnancy
using The Health Improvement Network (THIN) primary care database. Subsequently, we
used a Kaplan-Meier plot to compare time to last prescription in women prescribed lithium
continuously three months before pregnancy and a comparison group of non-pregnant
women. Finally, we described the characteristics of the women prescribed lithium
in pregnancy.
Results
Very few women were prescribed lithium during pregnancy; out of 458,761 pregnancies, we
identified 47 (0.01%) in which lithium was prescribed after the 6th week of pregnancy (when
the pregnancy was likely to be known). In our study of discontinuation, we found pregnant
women were more likely to stop lithium than those who were not pregnant. Of the 52 women
who were being continuously prescribed lithium three months before pregnancy, only 17
(33%) continued receiving prescriptions beyond the 6th week of pregnancy. However, most
of these 17 women continued treatment throughout pregnancy.
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Pregnancy was strongly associated with discontinuation of lithium. Further evidence on the
risks of lithium is needed so that women can weight these against the risk of a deterioration
in maternal mental health.
Introduction
Lithium is an effective drug for the treatment of bipolar disorder and treatment resistant de-
pression. Women who are taking lithium face a difficult decision about whether or not to stop
their medication if they conceive or plan to conceive. Lithium has been linked in the past to an
increased risk of congenital cardiac abnormalities, and in particular Ebstein’s anomaly.[1,2]
More recent studies have failed to find statistically significant evidence of an association,[3] but
the small numbers of women taking lithium in all of these studies mean that considerable un-
certainty remains. This potential risk of harm to the unborn baby must be balanced against the
increased risk of relapse if the mother stops her medication during pregnancy,[4] which may
cause great distress with the potential for adverse outcomes in both mother and baby.
The National Institute for Health and Care Excellence (NICE) 2014 guideline on antenatal
and postnatal mental health advises that lithium should not be offered to women who are plan-
ning pregnancy or are pregnant unless antipsychotic medication has not been effective.[5]I fa
woman becomes pregnant while taking lithium, the guideline recommends considering gradu-
ally stopping lithium over 4 weeks if the woman is well. For women who are not well or are at
high risk of relapse, recommended options include switching gradually to an antipsychotic,
stopping lithium and restarting in the second trimester or continuing lithium if an antipsychot-
ic is unlikely to be effective. However, there is little information available about what propor-
tion of women who are taking lithium before pregnancy actually stop their medication when
they become pregnant. The aims of this study were to investigate the prevalence of lithium pre-
scribing during pregnancy and to explore discontinuation of lithium during pregnancy. We
also examined how many women restarted lithium during and after pregnancy as well as the
prescribing of alternative medications during this period.
Methods
Data
The data for this study come from The Health Improvement Network (THIN) (http://
csdmruk.cegedim.com/), a UK primary care database containing the electronic health records
of approximately 12 million patients who have received care from a general practitioner (GP,
or family doctor). THIN is broadly generalisable to the UK population in terms of demograph-
ics and prevalence of major diseases.[6] The database contains records of all prescriptions is-
sued by a GP—most prescribing in the UK is performed by GPs, even when the decision to
initiate a particular drug is made by a hospital specialist.
For this study, we identified women who were pregnant between 1
st January 1995 and 31
st
December 2012. We calculated the start dates and durations of pregnancies using the last men-
strual period date, antenatal and postnatal care records, delivery information and records of
gestational age at birth; where there was no information on the duration of pregnancy, this was
assumed to be 280 days. The pregnancy start date was defined as the first day of the woman’s
last menstrual period. Women were required to be permanently registered with the same GP
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with records indicating miscarriages and terminations since there was limited information
with which to estimate the pregnancy start date for these women. The resulting cohort com-
prised 458,761 pregnancies.
First, we identified women receiving any lithium prescription in the 6 months before preg-
nancy, during pregnancy (at any time) and during pregnancy (after the first 6 weeks).
Women were included in the lithium discontinuation study if they were being prescribed
lithium continuously 91 days before the start of pregnancy; this was defined as receiving at
least one lithium prescription during the 183–92 days before the start of pregnancy, followed
by at least one further prescription during the 91–1 days before the start of pregnancy (and no
more than 91 days after the preceding prescription). We included prescriptions for lithium car-
bonate and lithium citrate (chapter 4.2.3 of the British National Formulary). We considered a
prescription to be the last in a period of prescribing if there were no subsequent prescriptions
issued in the following 91 days. The majority of women received prescriptions that lasted for
one or two months. To allow room for women to return to receive a repeat prescription earlier
or later we set the cut-off at 91 days.
One woman had two eligible pregnancies and we randomly selected one of these
for inclusion.
We also selected a comparison group of twice as many non-pregnant women prescribed
lithium. To do this, we identified ‘non-pregnant’ periods between 1
st January 1995 and 31
st De-
cember 2012 for all women aged 14–50 included in THIN: these were at least 1 year after the
end of any previous pregnancy and a minimum of 2 years before any subsequent pregnancy.
We randomly selected an index date within these non-pregnant periods to simulate the preg-
nancy start date. We then identified women who were being prescribed lithium 91 days before
the index date, and randomly sampled 2 non-pregnant women for each pregnant woman se-
lected earlier, stratified within 5 year age bands.
Analysis
First, we described the prevalence of lithium prescribing before and during pregnancy, strati-
fied by 3 year calendar periods.
For our study on discontinuation, we then used the cohort of women who were continu-
ously prescribed lithium before pregnancy and analysed time to last prescription of lithium
using Kaplan-Meier survival curves: follow-up started at 91 days before the start of pregnancy,
and was censored either at 220 days after the start of pregnancy (two months before a full-term
delivery) or at the actual date of delivery for premature births before this date. We described
the characteristics of the women who continued treatment after 6 weeks and those who
stopped, but did not attempt further statistical analyses because of the small numbers pre-
scribed lithium before pregnancy. We compared the two groups on age, prior continuous time
on lithium, parity and other medication prescribed in the 183–92 days before pregnancy—
where parity was not recorded in the mother’s medical record, we estimated parity using the
number of previous deliveries and older children in the household. Finally, we identified
women who restarted lithium prescriptions during and after pregnancy, as well as those pre-
scribed alternative medications. The data were analysed in Stata version 12.1 for PC.
Ethics statement
Ethical approval for the use of anonymised patient data from THIN for scientific research was
provided by the National Health Service South-East Multicentre Research Ethics Committee
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Results
Prevalence of lithium prescribing in pregnancy
From the cohort of 458,761 pregnancies, we identified only 67 pregnancies (0.015%) in which
the woman received one or more prescriptions of lithium at any time during pregnancy. How-
ever, this included only 47 (0.010%) pregnancies in which the woman received further pre-
scriptions after six weeks, at which point the woman was likely to be aware of the pregnancy.
The prevalence of lithium prescribing before and during pregnancy remained very low between
1995 and 2012 (Table 1).
Discontinuation of lithium before and during pregnancy
In our discontinuation cohort, we identified 52 women who were being prescribed lithium con-
tinuously 91 days before the start of their pregnancy. Of these women, many discontinued
treatment either before or in the first few weeks of pregnancy (Fig. 1). Only 33% (17 women)
continued to receive prescriptions after the 6
th week of pregnancy (by which time they were
likely to be aware that they were pregnant). However, 15 out of these 17 women continued to
receive prescriptions throughout pregnancy. Table 2 compares some of the characteristics of
those who continued to receive prescriptions beyond 6 weeks with those who stopped before
this date. A greater proportion of those who continued had been prescribed an antidepressant
(47%) or antipsychotic (53%) in addition to lithium during the 183–92 days before pregnancy
(compared to 34% prescribed antidepressants or antipsychotics in those who stopped). In addi-
tion, a greater proportion of those who continued lithium were having their first child (59%
versus 40%) or had been receiving continuous lithium prescriptions for less than 6 months
(47% versus 31%). However, the small numbers of women involved mean that the confidence
intervals for these percentages are wide and generally overlap (see Table 2).
Of the 39 pregnant women who stopped lithium prescriptions in Fig. 1, only 7 received pre-
scriptions for an antipsychotic or anticonvulsant mood stabiliser in the three months after dis-
continuing lithium. Four of the 39 women restarted lithium prescriptions during pregnancy.
Many more restarted after delivery; six months after delivery, 57% of the original cohort were
receiving prescriptions for lithium (29/51, with 1 woman lost to follow-up after delivery), and
the proportion receiving prescriptions remained stable beyond this point.
Table 1. Prevalence of lithium prescribing to pregnant women over time, before and during pregnancy.
Period Prescribed in 6m
before pregnancy
Prescribed during
pregnancy (any
time)
Prescribed during
pregnancy (after
ﬁrst 6 weeks)
Total pregnancies
n% n% n% n
1995–1997 8 0.019 8 0.019 8 0.019 42,239
1998–2000 17 0.026 10 0.015 8 0.012 65,955
2001–2003 17 0.022 12 0.016 7 0.009 75,806
2004–2006 18 0.021 13 0.015 6 0.007 87,262
2007–2009 17 0.018 10 0.011 7 0.007 94,617
2010–2012 17 0.018 14 0.015 11 0.012 92,882
All years 94 0.020 67 0.015 47 0.010 458,761
doi:10.1371/journal.pone.0121024.t001
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pregnant
Women may discontinue lithium for many reasons even when they are not pregnant. To illus-
trate this, Fig. 1 also shows the time to last prescription in a group of women who were not
pregnant: 88% (91 out of 104) were still receiving continuous prescriptions 6 weeks after the
randomly selected index date, while 77% (80 out of 104) were still receiving prescriptions at the
end of the follow-up period illustrated.
Discussion
We found that pregnancy is a strong predictor of lithium discontinuation in women who were
being prescribed the drug before they became pregnant. Only 33% of women who were being
prescribed lithium 3 months before the start of pregnancy received further prescriptions
after the 6
th week of pregnancy. Most of those who discontinued were not prescribed an alter-
native mood stabiliser or antipsychotic and few restarted lithium during pregnancy. However,
6 months after delivery 57% of the original cohort were being prescribed lithium.
A number of women received their last prescription before the start of pregnancy; this sug-
gests that these women stopped taking lithium before they became pregnant. However, we can-
not know exactly when women discontinued, particularly since they may have been advised to
reduce the dose gradually following their final prescription. We noted that many women had
also been receiving antidepressants and antipsychotics alongside lithium prior to pregnancy. It
is possible that co-medication is a marker for severity of the underlying illness, although we
Fig 1. Discontinuation of lithium in pregnant and non-pregnant women.
doi:10.1371/journal.pone.0121024.g001
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tinued lithium and those who stopped.
The pregnant women in our study were much more likely to discontinue lithium than our
comparison group. However, women who become pregnant may differ in important ways
from those who do not. For example, the severity of their underlying illness may be different.
Therefore, we cannot attribute the difference in discontinuation of lithium solely to the preg-
nancy. However, the fact that many women restarted lithium in the 6 months after delivery
suggests that pregnancy did contribute to their stopping.
It seems likely that many of the women who discontinued lithium did so because of con-
cerns around the safety of lithium during pregnancy and breastfeeding. Also, it is plausible that
many women on lithium treatment may elect not to become pregnant or terminate the preg-
nancy for various reasons. This may partly explain why we identified relatively few pregnant
women who were prescribed lithium before pregnancy. It is also possible that for various rea-
sons lithium is now being used less in the management of bipolar disorders and other mood
stabilisers and antipsychotic drugs are being preferred. However, the teratogenic risks of lithi-
um may have been overstated.[3] Furthermore, concerns about the potential harm of lithium
must be weighed against the risk of deterioration in maternal mental health after stopping lithi-
um,[4] and the importance of giving mother and child a stable and secure start to life together.
Other studies on discontinuation of psychotropic medication in pregnancy demonstrate re-
markably similar patterns to the ones we found on lithium. Thus, Petersen et al. showed that of
women prescribed antidepressants prior to pregnancy only 1060/5229 (20%) women contin-
ued to receive prescriptions beyond 6 weeks of pregnancy. [7] Man et al. found that women
with a diagnosis of bipolar disorder or depression prescribed antiepileptic drugs were also
Table 2. Comparing the characteristics of those who continue to receive lithium prescriptions beyond 6 weeks and those who stop.
Stopped before 6 weeks (n = 35) Continued beyond 6 weeks (n = 17)
n % (95% CI) n % (95% CI)
Age band
<25 5 14.3 (5.9, 30.8) 0 0.0 -
25–29 8 22.9 (11.5, 40.2) 4 23.5 (8.6, 50.1)
30–34 10 28.6 (15.7, 46.2) 7 41.2 (20.2, 66.0)
35+ 12 34.3 (20.2, 51.9) 6 35.3 (16.0, 60.9)
Prior continuous time on lithium
<6 months 11 31.4 (17.9, 49.0) 8 47.1 (24.5, 70.8)
6–12 months 6 17.1 (7.7, 34.0) 2 11.8 (2.7, 38.8)
>12 months 18 51.4 (34.7, 67.8) 7 41.2 (20.2, 66.0)
Estimated parity
0 14 40.0 (24.8, 57.4) 10 58.8 (34.0, 79.8)
1 13 37.1 (22.5, 54.6) 4 23.5 (8.6, 50.1)
2 6 17.1 (7.7, 34.0) 3 17.6 (5.4, 44.4)
3 or more 2 5.7 (1.4, 21.1) 0 0.0 -
Also taking an antidepressant 12 34.3 (20.2, 51.9) 8 47.1 (24.5, 70.8)
Also taking an antipsychotic 12 34.3 (20.2, 51.9) 9 52.9 (29.2, 75.5)
Also taking an anticonvulsant 6 17.1 (7.7, 34.0) 3 17.6 (5.4, 44.4)
Notes: Prior continuous time on lithium was measured up to the 91
st day before the start of pregnancy. Antidepressants, antipsychotics and
anticonvulsants were recorded in the 183–92 days before the start of pregnancy. Where parity was not recorded in the mother’s medical records, we also
looked at numbers of previous deliveries and older children in the household.
doi:10.1371/journal.pone.0121024.t002
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tinued prescriptions beyond 6 weeks of pregnancy.[8]
Our study highlights a key difficulty in evaluating lithium use and safety during pregnancy:
despite using data from a very large primary care database, we still only identified a very small
number of women who were prescribed lithium before and during pregnancy. A recent system-
atic review also identified this as an issue.[3] Another key limitation when using prescribing
data is that we do not know whether women actually took the medication that they were pre-
scribed, and for those who discontinued we cannot determine the exact date on which they
stopped taking the drug. However, studies that are based on interviews or questionnaires may
also face difficulties in achieving exact information on drug usage.
While women who are prescribed lithium in the United Kingdom are most likely to receive
this from primary care (since this is where the prescribing budget lies), we cannot rule out the
possibility that some women received prescriptions from specialist mental health services dur-
ing pregnancy (which would not be recorded in electronic primary care records). This may
particularly be an issue for women who were admitted to hospital following a relapse. Thus, we
may have slightly over-estimated the level of discontinuation.
We found the prevalence of lithium prescribing during pregnancy was very low. The majori-
ty of women who were prescribed lithium 3 months before becoming pregnant stopped receiv-
ing prescriptions by the 6
th week of pregnancy. Decisions about medication during pregnancy
will always require weighing up the benefits and risks, but such judgements are made much
harder when the risks are so uncertain. This highlights the urgent need for further research
into the safety of lithium in pregnancy and the need for unbiased reporting of both positive
and negative results, even if each small study can only contribute a small piece to the
overall puzzle.
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